Biogen to acquire RayThera for up to $1B in immunology push

What's the deal? BiogenDealroom has a profile for this one. Try Dealroom → (Nasdaq: BIIB) has agreed to acquire RayThera, a private San Diego-based biotech, for up to $1 billion. The deal consists of an upfront payment plus payments contingent on future clinical and regulatory milestones. RayThera develops small-molecule therapies for immune-mediated conditions, and its lead candidate is expected to enter Phase 1 development in early Q3 2026.

The transaction is subject to customary regulatory approvals and is anticipated to close in Q3 2026. Once completed, Biogen will lead development, manufacturing and global commercialisation of RayThera's assets. RayThera was co-founded by Qing DongDealroom has a profile for this one. Try Dealroom → and Gene HungDealroom has a profile for this one. Try Dealroom →, and recently completed its Series A financing co-led by Foresite Capital and OrbiMed, with participation from TTM CapitalDealroom has a profile for this one. Try Dealroom →.

Why now? Biogen is looking to deepen its immunology pipeline as it faces pressure to diversify beyond its core neuroscience portfolio. RayThera's assets are early-stage but span multiple indications, giving Biogen a broader foothold in the anti-inflammatory space.

The signal: Big pharma continues to scoop up early-stage biotechs to fill pipeline gaps, particularly in immunology — one of the industry's most competitive therapeutic areas. Milestone-heavy deal structures like this one let acquirers manage risk while still securing promising assets before rivals do.

Read more: Biogen · GlobeNewswire · Reuters